ONE KENDALL SQUARE, CAMBRIDGE, MA
CAMP4 Therapeutics Enters Underwriting Agreement for 5 Million Shares
Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Initiates GLP Toxicology Studies for CMP-SYNGAP-01
Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Earnings Release
Shareholder votes
Investor Presentation
Reports First Quarter 2025 Financial Results and Corporate Highlights
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Free Writing Prospectus